Breaking News, Financial News

Roche FY Revenues up 1%

Ronapreve approved in Europe to treat non-hospitalized COVID-19 patients and for prophylaxis had sales of CHF 1.6 billion.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Roche FY Revenues: 62.8 billion CHF (+8%) FY Earnings: 14.9 billion CHF (-1%) Comments: Pharmaceuticals Division sales increased 1% to 45.0 billion CHF with continued strong sales for newly launched medicines helping to offset impact of biosimilars. Actemra/RoActemra sales were CHF 3.6 billion, +27%. Avastin sales were CHF 3.1 billion, -37%. Herceptin sales were CHF 2.7 billion, -28%. MabThera/Rituxan sales were CHF 2.6 billion, -38%. Xolair sales were CHF 1.9 billion, +5%, (U.S. onl...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters